H-Lys-Lys-Arg-Ala-Ala-Arg-Ala-Thr-Ser-NH2

Myosin light chain kinase fragment 11-19 amide (MLCK(11-19) amide) is a substrate-specific peptide inhibitor of MLCK. Myosin light chain kinase fragment 11-19 amide inhibits hypotonicity-induced Ca2+ entry. Myosin light chain kinase fragment 11-19 amide can be used in the research of human cervical cancer[1][2].

[1] Aromolaran AS, et al. Evidence for myosin light chain kinase mediating noradrenaline-evoked cation current in rabbit portal vein myocytes. J Physiol. 2000 May 1;524 Pt 3(Pt 3):853-63. DOI:10.1111/j.1469-7793.2000.00853.x
[2] Shen MR, et al. Myosin light chain kinase modulates hypotonicity-induced Ca2+ entry and Cl- channel activity in human cervical cancer cells. Pflugers Arch. 2002 May;444(1-2):276-85. DOI:10.1007/s00424-002-0811-3
[3] Chilcoat CD, et al. Tonic protein kinase A activity maintains inactive beta2 integrins in unstimulated neutrophils by reducing myosin light-chain phosphorylation: role of myosin light-chain kinase and Rho kinase. J Leukoc Biol. 2008 Apr;83(4):964-71. DOI:10.1189/jlb.0405192